References
- de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675–686
- Pollicardo N, O'Brien S, Estey E H, al-Bitar M, Pierce S, Keating M, Kantarjian H M. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia 1996; 10: 27–31
- Beaumont M, Sanz M, Carli P M, Maloisel F, Thomas X, Detourmignies L, et al. Therapy-related acute promyelocytic leukaemia. J Clin Oncol 2003; 21: 2123–2137
- Mistry A R, Felix C A, Whitmarsh R J, Mason A, Reiter A, Cassinat B, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukaemia. N Engl J Med 2005; 352: 1529–1538
- Fenaux P, Le Deley M C, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukaemia: results of a multicenter randomized trial. Blood 1993; 82: 3241–3249
- Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all-trans retinoic acid and (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192–1200
- Tallman M S, Nabhan C, Feusner J H, Rowe J M. Acute promyelocytic leukemia: evolving strategies. Blood 2002; 99: 759–767
- Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramaniam P, et al. Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627–2632
- Alimoghaddam K, Shariftabrizi A, Tavanger M, Sanaat Z, Rostami S, Jahani M, Ghavamzadeh A. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukaemia. Leuk Lymphoma 2006; 47: 81–88
- Raffoux E, Rousselot P, Poupon J, Daniel M T, Cassinat B, Delarue R, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukaemia. J Clin Oncol 2003; 21: 2326–2334
- Shigeno K, Naito K, Sahara M, Kobayashi M, Nakamura S, Fujisawa S, et al. Arsenic trioxide in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Haematol 2005; 82: 224–229